Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research

BACKGROUND: Optimal Phase‐II design to evaluate new therapies in refractory/relapsed Ewing sarcomas (ES) remains imperfectly defined. OBJECTIVES: Recurrent/refractory ES phase‐I/II trials analysis to improve trials design. METHODS: Comprehensive review of therapeutic trials registered on five databa...

Descripción completa

Detalles Bibliográficos
Autores principales: Felix, Arthur, Berlanga, Pablo, Toulmonde, Maud, Landman‐Parker, Judith, Dumont, Sarah, Vassal, Gilles, Le Deley, Marie‐Cécile, Gaspar, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940237/
https://www.ncbi.nlm.nih.gov/pubmed/33452711
http://dx.doi.org/10.1002/cam4.3712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940237/
https://www.ncbi.nlm.nih.gov/pubmed/33452711
http://dx.doi.org/10.1002/cam4.3712

Ejemplares similares